|
Re: The countdown to 250
|
3
|
Resverlogix Corp.
|
Oct 12, 2018 11:41AM
|
|
Re: Arvinas /ARVN dBET vs iBET
|
4
|
Zenith Epigenetics
|
Oct 13, 2018 03:41PM
|
|
Re: Resverlogix H2 2018 events
|
4
|
Resverlogix Corp.
|
Oct 16, 2018 11:51AM
|
|
Re: BTI just filed a Other securityholders documents - English
|
3
|
BIOASIS TECHNOLOGIES INC
|
Oct 16, 2018 01:22PM
|
|
HDL function is associated with atherosclerotic burden and cardiovascular outcomes in T2D
|
4
|
Resverlogix Corp.
|
Oct 16, 2018 04:34PM
|
|
Epigenetic drugs, cardiometabolic disease and atherosclerosis
|
3
|
Resverlogix Corp.
|
Oct 16, 2018 04:45PM
|
|
Re: HDL function is associated with atherosclerotic burden and cardiovascular outcomes in T2D
|
2
|
Resverlogix Corp.
|
Oct 16, 2018 06:45PM
|
|
Re: Jardiance??
|
4
|
Resverlogix Corp.
|
Oct 16, 2018 11:57PM
|
|
Re: Jardiance??
|
2
|
Resverlogix Corp.
|
Oct 17, 2018 09:49AM
|
|
Re: Jardiance??
|
4
|
Resverlogix Corp.
|
Oct 17, 2018 12:23PM
|
|
Re: BiOasis Presents at BIO Investor Forum Oct 17th
|
3
|
BIOASIS TECHNOLOGIES INC
|
Oct 17, 2018 07:59PM
|
|
Re: Resverlogix October 2018 events
|
3
|
Resverlogix Corp.
|
Oct 17, 2018 10:18PM
|
|
Re: Zenith presents at BIO Investor Forum Oct 17th
|
4
|
Zenith Epigenetics
|
Oct 17, 2018 10:19PM
|
|
Re: Resverlogix October 2018 events
|
6
|
Resverlogix Corp.
|
Oct 18, 2018 08:46AM
|
|
Re: Resverlogix October 2018 events
|
4
|
Resverlogix Corp.
|
Oct 18, 2018 09:50AM
|
|
Re: Must be a dilutive financing in the works...
|
2
|
Resverlogix Corp.
|
Oct 18, 2018 09:53AM
|
|
Re: Must be a dilutive financing in the works...
|
1
|
Resverlogix Corp.
|
Oct 18, 2018 11:32AM
|
|
Re: Must be a dilutive financing in the works...
|
4
|
Resverlogix Corp.
|
Oct 18, 2018 12:35PM
|
|
CANTOS good, but FDA not on board with sub-group analysis
|
6
|
Resverlogix Corp.
|
Oct 18, 2018 02:03PM
|
|
Re: Endocyte Valuation
|
2
|
Zenith Epigenetics
|
Oct 18, 2018 02:35PM
|
